Preclinical study demonstrates high efficacy of dual PPARalpha/gamma agonists in animal models of type 2 diabetes and dyslipidemia, suggesting potential for balanced metabolic therapy.
An X-ray-guided design approach led to the identification of a novel, balanced class of alpha-ethoxy-phenylpropionic acid-derived dual PPARalpha/gamma agonists. The series shows a wide range of PPARalpha/gamma ratios within a rather narrow structural space. Advanced compounds possess favorable physicochemical and pharmacokinetic profiles and show a high efficacy in T2D and dyslipidemia animal models.
No takes yet. Share an insight, caveat, or question.
Grether et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: